Open Access

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma

  • Authors:
    • Hiroaki Kato
    • Tokuzo Arao
    • Kazuko Matsumoto
    • Yoshihiko Fujita
    • Hideharu Kimura
    • Hidetoshi Hayashi
    • Kouhei Nishiki
    • Mitsuru Iwama
    • Osamu Shiraishi
    • Atsushi Yasuda
    • Masayuki Shinkai
    • Motohiro Imano
    • Haruhiko Imamoto
    • Takushi Yasuda
    • Kiyotaka Okuno
    • Hitoshi Shiozaki
    • Kazuto Nishio
  • View Affiliations

  • Published online on: February 19, 2013     https://doi.org/10.3892/ijo.2013.1830
  • Pages: 1151-1158
  • Copyright: © Kato et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Molecular targeted therapy is expected to be a promising therapeutic approach for the treatment of esophageal squamous cell carcinoma (ESCC); however, the gene amplification status of molecular targeted genes in ESCC remains largely unclear. The gene amplification of EGFR, HER2, FGFR2 and MET was examined using a real-time PCR-based copy number assay of 245 ESCC surgical specimens of formalin-fixed, paraffin-embedded samples. Fluorescence in situ hybridization (FISH) and comparative genomic hybridization analyses verified the results of the copy number assay. EGFR mutation was detected using the Scorpions-ARMS method. The EGFR status and drug sensitivity to an EGFR tyrosine kinase inhibitor was then evaluated in vitro. Gene amplification of EGFR and HER2 was observed in 7% (16/244) and 11% (27/245) of the ESCC specimens. A multivariate analysis revealed that HER2 amplification was a significant predictor of a poor prognosis in patients with stage III post-operative ESCC. The L861Q type of EGFR mutation with hypersensitivity to EGFR tyrosine kinase inhibitor was found in one of the eight ESCC cell lines and one del745 type of EGFR mutation was identified in 107 clinical samples. In addition, we demonstrated for the first time that FGFR2 amplification was observed in 4% (8/196) of the ESCC specimens. MET amplification was observed in 1% (2/196). In conclusion, the frequent gene amplification of EGFR, HER2 and FGFR2 and the presence of active EGFR mutations were observed in ESCC specimens. Our results strongly encourage the development of molecular targeted therapy for ESCC.
View Figures
View References

Related Articles

Journal Cover

April 2013
Volume 42 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kato, H., Arao, T., Matsumoto, K., Fujita, Y., Kimura, H., Hayashi, H. ... Nishio, K. (2013). Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. International Journal of Oncology, 42, 1151-1158. https://doi.org/10.3892/ijo.2013.1830
MLA
Kato, H., Arao, T., Matsumoto, K., Fujita, Y., Kimura, H., Hayashi, H., Nishiki, K., Iwama, M., Shiraishi, O., Yasuda, A., Shinkai, M., Imano, M., Imamoto, H., Yasuda, T., Okuno, K., Shiozaki, H., Nishio, K."Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma". International Journal of Oncology 42.4 (2013): 1151-1158.
Chicago
Kato, H., Arao, T., Matsumoto, K., Fujita, Y., Kimura, H., Hayashi, H., Nishiki, K., Iwama, M., Shiraishi, O., Yasuda, A., Shinkai, M., Imano, M., Imamoto, H., Yasuda, T., Okuno, K., Shiozaki, H., Nishio, K."Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma". International Journal of Oncology 42, no. 4 (2013): 1151-1158. https://doi.org/10.3892/ijo.2013.1830